The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Non-Executive Directors

1 Jul 2013 09:41

RNS Number : 2542I
Akers Biosciences, Inc.
01 July 2013
 



 

1 July 2013

 

 

Akers Biosciences, Inc.

 

("ABI" or the "Company")

 

Appointment of Non-Executive Directors

 

Akers Biosciences, Inc (AIM: AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, today announces that Gavin Moran and Thomas Knox will be appointed to the board as Non-Executive Directors with effect from 1 July 2013.

 

Mr Moran, aged 43, is an Irish national who has previously worked for Shell International in Shell Chemicals, Marketing, Finance and Shell International Trading. He then held a Trading role as a beneficial shareholder at Trafigura, a leading international commodities trading and logistics company based in Amsterdam and then a Trading role as a beneficial shareholder at Sono International based in London. Mr Moran is indirectly interested through Chubeworkx Guernsey Limited, in which he holds a 31.69 per cent. shareholding, 80 million common shares in the Company, which represents 28.70 per cent of the Company's shares and 24.30 per cent. of the Company's voting rights.

 

Mr Knox, aged 72, is a Philadelphia, Pennsylvania-based businessman who has owned, managed, and ultimately sold multiple profitable companies in the software, banking, and health insurance industries including Disc Systems, Inc., Crusader Bank, Gimco International, Kasser Industries and Fidelity Insurance Group. He also served as Chief Executive Officer for United HealthCare of Pennsylvania and served as Special Deputy Rehabilitator & Chief Executive Officer of Fidelity Mutual Life Insurance Co., Pennsylvania's 5th largest insurer. He currently holds 30 million common shares and 10 million preference shares, which represents 10.76 per cent of the Company's shares and 28.78 per cent. of the Company's voting rights.

 

Raymond F. Akers, Executive Chairman of ABI commented, "It gives me great pleasure to welcome Gavin and Thomas to our Board. They have both invested in the company in the past year and bring with them expertise and experience, which will help move the company forward in the future. My colleagues and I are very much looking forward to our working together."

Further information concerning Mr Moran

Gavin Edwin David Moran's directorships (current and within the previous 5 years) are as follows:

 

Current: None

 

Past: None

 

Further information concerning Mr Knox

 

Thomas James Knox, a Chartered Life Underwriter (CLU) and Chartered Financial Consultant (ChFC), has been involved in Philadelphia politics having held the position of Deputy Mayor for the Office of Management and Productivity. Mr Knox is the Chief Executive Officer of Knox Consulting Group, Knox Family Loan Company and INDECS Corp.

Thomas James Knox's directorships (current and within the previous 5 years) are as follows:

 

Current: Knox Consulting Group

Knox Family Loan Company

INDECS Corp

Historic Philadelphia, Inc.

Newman Wine and Spirit Company

ORB Automotive based in Shenzhen, China

 

Past: None

 

There is no further information required relating to Thomas J. Knox or Gavin E.D. Moran to be disclosed under paragraph (g) of Schedule 2 of the AIM Rules.

 

Enquiries:

Thomas A. Nicolette, President and CEO

Tel. +1 856 848 8698

Antony Legge / James Thomas

Daniel Stewart (Nomad and Broker)

 

 

 

Tel. +44 (0)20 7776 6550

 

 

About Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com

 

End

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAVFLBBXDFXBBK
Date   Source Headline
31st Dec 20157:00 amRNSIssue of Equity & Directors' Shareholdings
1st Dec 20157:00 amRNSAkers Biosciences Updates on JV in China
23rd Nov 20157:00 amRNSAppointment of CEO
13th Nov 20157:00 amRNS3rd Quarter Results
12th Nov 201512:00 pmRNSAppointment of Non-Executive Director
11th Nov 20157:00 amRNSNotice of Q3 Results
4th Nov 20157:00 amRNSHIT Test Approved by Chinese FDA
6th Oct 20157:00 amRNSCommercialization of New Breath Tests
30th Sep 20157:00 amRNSDistribution Agreements
14th Sep 20157:00 amRNSLaunch of Breath Ketone test
18th Aug 20157:00 amRNSHalf Yearly Report
14th Aug 20157:00 amRNSNotice of Half Yearly Results
13th Aug 20157:00 amRNSNotice of Half Yearly Results
3rd Aug 20155:29 pmRNSResult of AGM
30th Jun 20152:00 pmRNSAppointment of Non-Executive Director
25th Jun 20155:00 pmRNSAdjournment of Annual General Meeting
16th Jun 20152:30 pmRNSUpdate on Rapid Breath Tests for Wellness Industry
5th Jun 20153:45 pmRNSNotice of AGM and Proposed Board Changes
14th May 20157:00 amRNS1st Quarter Results
12th May 20157:20 amRNSAkers Introduces New Rapid Breath Tests
11th May 20155:50 pmRNSNotice of Q1 Results
11th May 20157:00 amRNSClaim Against ChubeWorkx Guernsey Limited
6th May 20157:01 amRNSResale Agreement
13th Apr 20157:00 amRNSDistribution Agreements
2nd Apr 20157:00 amRNSDistribution Agreement
23rd Mar 201510:52 amRNSFinal Results
19th Mar 20157:00 amRNSNotice of Results
9th Feb 201512:00 pmRNSAkers' Management System Certified to ISO 13485
26th Jan 20157:00 amRNSEuropean Patent Granted
20th Jan 20157:00 amRNSExpansion of US Sales Effort with Key Appointments
9th Jan 20153:03 pmRNSIssue of Equity
9th Jan 20157:00 amRNSIncentive Stock and Award Plan
18th Dec 20147:00 amRNSEuropean Distribution Agreements
10th Dec 20147:00 amRNSOrder to Supply PIFA Products to China
13th Nov 201412:00 pmRNSThird Quarter Results
10th Nov 201412:00 pmRNSNotice of Third Quarter Results
4th Nov 20144:49 pmRNSResult of AGM
23rd Oct 20141:20 pmRNSJV to Market Rapid Diagnostic Tests in China
17th Oct 20143:10 pmRNSNotice of AGM
16th Sep 20145:53 pmRNSAKERS BIOSCIENCES FEATURES ON GLOBAL MEDIA
9th Sep 201412:30 pmRNSSALES CONTRACT FOR RAPID CHOLESTEROL TEST
8th Sep 20147:00 amRNSChange of Adviser
15th Aug 20147:00 amRNSAppointment of Co-chairman
12th Aug 201411:00 amRNSHalf Yearly Report
5th Aug 20147:00 amRNSSenior Managerial Appointment
28th Jul 20147:00 amRNSFeasibility Study For Heart Attack Test
17th Jul 20147:00 amRNSUS Patent - Breath Ketone Detection Device
30th Jun 20147:00 amRNSPosting of Annual Report and Accounts
25th Jun 20147:00 amRNSUS Distribution Agreement
13th Jun 201411:11 amRNSGrant of Options and Directors Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.